So your analysis is that this is a non-issue because you simply are dismissing the PR? Whew! That's a pretty risky way of approaching DD...at least I thnk so.
I didn't say it was a non-issue. I have always said that Insmed would perhaps be found to be infringing but as a worst case scenario they would have to pay a royalty after the appeals process.
What I do know is that I do not believe the tercica press releases
That is very different than the way you interpretted my response
How could the court rule that Insmed literally infringes 3 claims, when the summary judgement and arguments were only for 2 claims?
And, the ruling on the '151 patent (growth patent) merely says that the patent cannot be ruled invalid as a summary judgement. There is absolutely no statement by the judge affirming infringement.
News 
Market Data 
Discover 
